Novavax has secured a $125 million milestone payment as Sanofi launched a Phase 3 clinical trial in Europe for a combined influenza and COVID-19 vaccine. The trial advanced after the fifth participant was dosed with the combination therapy.
In Plain English: The Clinical Takeaway
- Combination Vaccines: This trial tests whether a single injection can simultaneously protect against two distinct respiratory pathogens: influenza and SARS-CoV-2.
- Immunogenicity: Researchers are measuring how effectively the vaccine stimulates an immune response in older adults, specifically checking antibody production.
- Adjuvant Technology: The formulation incorporates Novavax’s proprietary adjuvant, Matrix-M, designed to enhance the body’s immune reaction.
Sanofi Advances European Phase 3 Trial Targeting Adults Aged 60 and Older
The European Phase 3 trial evaluates the safety and immunogenicity of Nuvaxovid—Novavax’s COVID-19 vaccine—administered in combination with Sanofi’s marketed Efluelda/Fluzone High-Dose vaccine. Investigators are focusing their evaluation on adults aged 60 and older. The dosing of the fifth patient triggered the $125 million financial milestone for Novavax under the ongoing collaboration and licensing agreement.
Global markets for influenza and COVID-19 immunizations currently exceed $10 billion in combined value, according to details released by Novavax via PR Newswire. John C. Jacobs, President and Chief Executive Officer of Novavax, stated that the partnership has generated over $1 billion in revenue for the company to date. Jacobs added that Sanofi intends to be one of the first movers in the combination vaccine segment.
Milestones and Licensing Framework Between Novavax and Sanofi
The collaboration agreement between the two drugmakers establishes a tiered structure for future payments tied to developmental and commercial benchmarks. Novavax is eligible to receive ongoing royalties on commercial sales of Nuvaxovid by Sanofi. An additional $75 million milestone payment is scheduled upon the successful completion of manufacturing technology transfer activities, which are anticipated by mid-2027.
Further financial triggers are linked to regulatory progress in the United States. Novavax stands to receive a $225 million milestone payment if a combined influenza and COVID-19 vaccine is successfully launched in the U.S. market, subject to Sanofi fulfilling all clinical and regulatory requirements in the U.S. The agreement also provides for royalties on any combination products developed by Sanofi using Nuvaxovid, alongside milestone payments and royalties for any new vaccines utilizing the Matrix-M adjuvant.
Contraindications & When to Consult a Doctor
Always consult a primary care physician or immunologist to assess personal risk factors, potential contraindications, and appropriate vaccination schedules.
Regulatory Hurdles and Forward-Looking Production Goals
While the European trial progresses, the path to a U.S. commercial launch involves distinct regulatory pathways. Additional clinical studies may be required to support regulatory filings in the U.S. market, given that the U.S. may have different regulatory requirements from other markets.
| Trial Parameter | Details |
|---|---|
| Vaccine Components | Nuvaxovid (Novavax) + Efluelda/Fluzone High-Dose (Sanofi) |
| Target Demographic | Adults aged 60 and older |
| Primary Endpoints | Safety and immunogenicity |
| Geographic Location | Europe |
| Current Milestone | $125 million paid upon fifth patient dosed |
